Nov. 1, 2024 — Recor Medical, Inc. and its parent company, Otsuka Medical Devices Co. recently announced U.S. Centers ...
November 20, 2023 — A groundbreaking advancement in the treatment of patients with uncontrolled hypertension (HTN) has ...
November 15, 2023 — Recor Medical, Inc. and its parent company, Otsuka Medical Devices Co., Ltd. announced the first ...
January 9, 2023 — ReCor Medical, Inc. and its parent company, Otsuka Medical Devices Co., Ltd. announced the appointment ...
September 26, 2022 — ReCor Medical, Inc., a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., announced the ...
May 16, 2021 — Two months after undergoing renal denervation (RDN) with the ReCor Paradise renal denervation system ...
May 31, 2018 – ReCor Medical announced that the RADIANCE-HTN SOLO study met its primary efficacy endpoint and ...
January 28, 2014 — ReCor Medical advanced its Paradise System for renal denervation (RDN) for treatment resistant ...
One of the exciting new frontiers for interventional cardiology is the use of renal denervation therapy to treat ...
April 11, 2012 — ReCor Medical disclosed updated data for the REDUCE First-In-Man clinical study of its CE-marked ...